Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
494.9 USD | +0.82% |
|
+1.32% | +21.02% |
12:55pm | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating | MT |
07-15 | Vertex Sues U.S. to Pay for Fertility Treatments | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.02% | 127B | |
+23.99% | 117B | |
+26.17% | 27.67B | |
-19.20% | 20.33B | |
-16.08% | 16.79B | |
-17.74% | 15.63B | |
+13.87% | 14.84B | |
-47.70% | 14.65B | |
+58.51% | 14.43B | |
+151.05% | 12.49B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-11-2021 06